- Home
- ACHV vs PAI Comparison
ACHV vs PAI Comparison
Compare ACHV & PAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- PAI
- Stock Information
- Founded
- ACHV N/A
- PAI 1973
- Country
- ACHV United States
- PAI United States
- Employees
- ACHV N/A
- PAI N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAI Trusts Except Educational Religious and Charitable
- Sector
- ACHV Health Care
- PAI Finance
- Exchange
- ACHV Nasdaq
- PAI Nasdaq
- Market Cap
- ACHV 153.8M
- PAI 123.5M
- IPO Year
- ACHV N/A
- PAI N/A
- Fundamental
- Price
- ACHV $3.15
- PAI $12.80
- Analyst Decision
- ACHV Strong Buy
- PAI
- Analyst Count
- ACHV 2
- PAI 0
- Target Price
- ACHV $16.00
- PAI N/A
- AVG Volume (30 Days)
- ACHV 867.2K
- PAI 25.0K
- Earning Date
- ACHV 11-06-2025
- PAI 01-01-0001
- Dividend Yield
- ACHV N/A
- PAI 4.78%
- EPS Growth
- ACHV N/A
- PAI N/A
- EPS
- ACHV N/A
- PAI N/A
- Revenue
- ACHV N/A
- PAI N/A
- Revenue This Year
- ACHV N/A
- PAI N/A
- Revenue Next Year
- ACHV N/A
- PAI N/A
- P/E Ratio
- ACHV N/A
- PAI N/A
- Revenue Growth
- ACHV N/A
- PAI N/A
- 52 Week Low
- ACHV $1.84
- PAI $10.59
- 52 Week High
- ACHV $5.31
- PAI $12.63
- Technical
- Relative Strength Index (RSI)
- ACHV 56.75
- PAI 49.97
- Support Level
- ACHV $3.07
- PAI $12.57
- Resistance Level
- ACHV $3.21
- PAI $12.90
- Average True Range (ATR)
- ACHV 0.14
- PAI 0.14
- MACD
- ACHV 0.01
- PAI -0.01
- Stochastic Oscillator
- ACHV 77.55
- PAI 52.27
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.